Where can I learn more about this study?
You can find more information about this study on the websites listed below. If more information
about the study results is available, it can also be found here.
X www.clinicaltrials.gov Once you are on the website, type “D5660C00016”
into the search box and click “Search”.
X www.AstraZenecaClinicalTrials.com Once you are on the website, type “NCT03421353”
into the search box, and click “Find a Study”.
Full Study Title: A Phase Ib/II, Open-Label, Multicentre Study to Assess Safety, Tolerability,
Pharmacokinetics, and Preliminary Anti-tumour Activity of AZD9150 plus Durvalumab alone or in
Combination with Chemotherapy in Patients with Advanced, Solid Tumours and Subsequently in
Patients with Non-Small-Cell Lung Cancer
AstraZeneca AB Protocol Number: D5660C00016
National Clinical Trials Number: NCT03421353
AstraZeneca AB sponsored this study and has its headquarters in Södertälje, Sweden
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you
Clinical study participants belong to a large community of people who take part in
clinical research around the world. They help researchers answer
important health questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization focused on
educating and informing the public about clinical research participation. CISCRP is not involved in recruiting participants
for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 1.0_2022_03_28
16 | Clinical Study Results